Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. (MLSS) is described in its public disclosures as a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company’s news flow centers on its computerized drug delivery instruments, which are designed to provide painless and precise injections using its DPS Dynamic Pressure Sensing Technology® platform.
News updates commonly cover developments in Milestone Scientific’s dental segment, including expansion of direct sales programs in North America, new international registrations for the STA® Single Tooth Anesthesia System, and initiatives such as The Wand® Ambassador Program. That program uses experienced dental professionals to share real-world clinical insights and workflow considerations to support broader adoption of The Wand STA System.
In the medical segment, news items highlight the CompuFlo® technology and the CompuFlo Epidural System, including growing utilization of CompuFlo disposables, interest from hospitals and international distributors, and progress on reimbursement strategies. Milestone Scientific reports milestones such as Medicare Part B payment-rate assignments under CPT® code 0777T in several jurisdictions and early activity from commercial insurers, which it views as important for adoption in interventional pain management and spine intervention markets.
Other recurring themes in Milestone Scientific’s news include quarterly financial results, cost-management and operational transformation efforts, leadership appointments, board changes, and updates on NYSE American listing compliance matters. Investors and observers can use this news stream to follow the company’s commercial initiatives in dental and medical markets, its reimbursement and payer-access efforts, and its corporate and governance developments over time.
Milestone Scientific (NYSE: MLSS) has appointed Ms. Benedetta Casamento to its Board of Directors. Casamento, a retail consultant with extensive experience in finance and brand management, was previously Chairman and President of Allyke, Inc., and has held top roles at Calypso St. Barth and The Talbots. Her expertise in marketing and operations is expected to bolster Milestone's growth strategies, particularly for its CompuFlo® Epidural and CathCheck™ products. Chairman Leslie Bernhard expressed confidence in her potential contributions to the company’s future.
Milestone Scientific Inc. (NYSE: MLSS) reported Q1 2022 revenues of $2.7 million, down from $2.9 million in Q1 2021. The decrease was attributed to prior year's pent-up demand. Despite the decline, the company is advancing sales efforts for its CompuFlo® Epidural and CathCheck™ systems and has secured vendor status with a major Northeast hospital. Operating loss rose to $(1.9) million. However, Milestone maintains a strong balance sheet with $13.3 million in cash and is well-positioned for growth, particularly in the dental segment amid expanding distribution partnerships.
Milestone Scientific Inc. (NYSE:MLSS) will host a conference call on May 17, 2022, at 8:30 AM ET to discuss its financial results for Q1 2022, ending March 31. The call aims to provide insights into the company's corporate progress and developments. U.S. callers can join by calling toll-free 888-506-0062, and international callers can reach +1 973-528-0011. An audio replay will be available until May 31, 2022. Milestone Scientific specializes in innovative injection technologies, enhancing patient comfort and safety.
Milestone Scientific (NYSE:MLSS) announced that its President and CEO, Arjan Haverhals, will present at the Noble Capital Markets Eighteenth Annual Investor Conference on April 21, 2022, at 11:30 am ET in Seminole Ballroom D. Investors can meet management at breakout sessions on April 20. A video webcast of the presentation will be available the following day on the company’s website and other platforms for 90 days. Milestone specializes in advanced drug delivery systems, enhancing patient comfort and safety through innovative technologies.
Milestone Scientific Inc. (NYSE: MLSS) has formed a strategic partnership with Keystone Dental Group to enhance the distribution of its STA Single Tooth Anesthesia® system in the dental implant market. This collaboration leverages Keystone's sales force of over 60 representatives to expand reach into surgical specialties. Additionally, Milestone has partnered with American Independent Dental Alliance to access over 1,000 dental practices, and with Esthetic Professionals to enhance dental education through hands-on training. These initiatives aim to drive growth in the expanding DSO market.
Milestone Scientific (NYSE: MLSS) has begun sales of its CompuFlo Epidural and CathCheck Verification System to a leading medical center recognized as one of the World’s Best Hospitals-USA for four consecutive years. The approval comes after a successful evaluation and emphasizes the systems' clinical advantages in improving accuracy and reducing complication rates during epidural procedures. These innovations aim to drive better health outcomes at lower costs, with potential economic benefits for healthcare institutions.
Milestone Scientific (NYSE: MLSS) reported a remarkable 90% year-over-year revenue growth for 2021, totaling $10.3 million, surpassing previous guidance and pre-pandemic levels. The company highlights strong dental division performance and profitability with high gross margins. Expansion in medical distribution includes new partnerships with pain management clinics and hospitals. Despite challenges from the pandemic, particularly in labor and delivery departments, Milestone is optimistic about regaining momentum. The company holds a robust cash position of $14.8 million to fuel growth initiatives.
Milestone Scientific (NYSE:MLSS) has announced a conference call set for April 1, 2022, at 8:30 AM ET to discuss its financial results for the fiscal year ending December 31, 2021. The call will cover corporate progress and developments. Investors can join via telephone or access a webcast on the company’s Investor Relations page. An audio replay will be available until April 15, 2022. Milestone Scientific specializes in computerized drug delivery instruments aimed at providing painless and precise injections, enhancing patient comfort and safety.
Milestone Scientific (NYSE:MLSS) has launched sales of its CompuFlo Epidural disposables at two California surgery centers: Cypress and Galileo. Both facilities, owned by Pain Management Specialists, will utilize Milestone's technology to enhance patient care. CEO Arjan Haverhals noted that this expansion follows successful evaluations of the system's safety and economic efficiency. Milestone is focused on developing advanced drug delivery systems to improve injection precision, comfort, and safety.
Milestone Scientific Inc. (NYSE: MLSS) is set to participate in The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Conference from February 8-11, 2022. CEO Arjan Haverhals will present on February 9 at 10:30 AM ET. The presentation can be accessed via webcast on the company's website. The conference includes 25-minute virtual presentations and one-on-one meetings for investors. This event showcases qualified institutional investors' best ideas.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
